Metropolis Healthcare Limited on Tuesday announced the launch of its Centre of Genomics, marking a strategic expansion of its advanced genomics, molecular diagnostics, and precision medicine capabilities in India. The company stated that the initiative is aimed at strengthening clinically actionable genomic insights across multiple high-impact specialties.
According to the company’s press release, the Centre of Genomics will be backed by two CAP-accredited national referral genomics laboratories located in Mumbai and Delhi NCR, following the integration of Core Diagnostics’ specialised genomics facility. These laboratories will support testing across oncology, reproductive health, neurology, transplant immunology, and rare diseases.
As part of the technology upgrade, Metropolis has deployed Illumina’s NovaSeq™ X Series for research purposes. The company said the system significantly enhances sequencing throughput and accuracy, with the NovaSeq™ X Plus capable of generating over 20,000 whole genomes annually, more than double the capacity of earlier platforms.
Metropolis currently offers over 220 validated genomic tests and plans to expand its portfolio to more than 500 advanced genomic assays over the next two to three years, the release noted. The Centre will also focus on AI-enabled analytics, test development, and deeper digital integration to improve reporting quality and clinical outcomes.
Commenting on the launch, Executive Chairperson Ameera Shah said genomics represents a critical inflection point for diagnostics in India, enabling risk prediction, therapy personalisation, and long-term disease management, supported by rigorous validation and clinical stewardship.
